Edition:
United Kingdom

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

7.20USD
15 Aug 2018
Change (% chg)

$-0.14 (-1.91%)
Prev Close
$7.34
Open
$7.26
Day's High
$7.36
Day's Low
$7.05
Volume
71,851
Avg. Vol
80,723
52-wk High
$15.20
52-wk Low
$6.15

Latest Key Developments (Source: Significant Developments)

Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Syndax Pharmaceuticals Inc ::PHASE 1 TRIAL OF SNDX-6352 IN CHRONIC GRAFT VERSUS HOST DISEASE EXPECTED TO COMMENCE BY END OF YEAR.PFS RESULTS FROM PIVOTAL PHASE 3 E2112 TRIAL OF ENTINOSTAT PLUS EXEMESTANE IN HR+, HER2- BREAST CANCER EXPECTED IN 3Q18.SYNDAX PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE.Q2 LOSS PER SHARE $0.74.Q2 EARNINGS PER SHARE VIEW $-0.87 -- THOMSON REUTERS I/B/E/S.SYNDAX PHARMACEUTICALS - FOR Q3 & FULL YEAR 2018, RESEARCH AND DEVELOPMENT EXPENSES ARE EXPECTED TO BE $14 TO $16 MILLION AND $59 TO $62 MILLION, RESPECTIVELY.  Full Article

Syndax And Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
Wednesday, 30 May 2018 

May 30 (Reuters) - Nektar Therapeutics ::SYNDAX AND NEKTAR THERAPEUTICS ANNOUNCE IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION.NEKTAR- ANNOUNCED NON-EXCLUSIVE, CLINICAL COLLABORATION TO EVALUATE SAFETY, EFFICACY OF NEKTAR'S NKTR-214, IN COMBINATION WITH SYNDAX'S ENTINOSTAT.NEKTAR THERAPEUTICS - COLLABORATION WILL EVALUATE COMBINATION OF ENTINOSTAT WITH NKTR-214 IN PATIENTS WITH PD-1 REFRACTORY MELANOMA.NEKTAR THERAPEUTICS - ADDITIONAL FINANCIAL DETAILS AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER.SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP.SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO'S ENTINOSTAT AND GENENTECH'S ATEZOLIZUMAB.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED..SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL.SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE'S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM.  Full Article

Syndax Pharmaceuticals reports Q3 loss per share $0.68
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update.Q3 loss per share $0.68.Q3 earnings per share view $-0.80 -- Thomson Reuters I/B/E/S.  Full Article

Syndax Pharma enters into license agreement with unit of Allergan
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Syndax Pharmaceuticals :On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing.Pursuant to agreement, co will make an upfront payment of $5.0 million to Allergan​.If parties commercialize Menin assets, co obligated to pay Allergan low single to low double-digit royalties on sales​.Under agreement, Allergan grants co worldwide license to portfolio of orally-available small molecule inhibitors of interaction of MLL protein​.Under agreement, may have to pay allergan up to $99 million in one-time development, regulatory milestone payments subject to achievement of milestones.In event of commercializing Menin assets, co to also pay up to $70 million in potential one-time sales-based milestone payments​.Company will be solely responsible for development and commercialization of Menin assets​.Under certain circumstances, co may be required to share a percentage of non-royalty income from sublicensees, with Allergan​.  Full Article

Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​.Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​.  Full Article

BRIEF-Syndax Pharmaceuticals Reports Q1 Loss Per Share $0.79

* SYNDAX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE